GuidelineNature reviews. Nephrology2019
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.
Guideline in Nature reviews. Nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 282 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
282 citing papers in PubMed, 1 synthesis or guideline pooled it, 513 citations in OpenAlex.
- Systematic review and meta-analysis of the clinical features of MGRS.BMC nephrology · 2024Pooled it
- Efficacy and safety of reduced-dose daratumumab plus bortezomib and dexamethasone (DVd-lite) in newly diagnosed MGRS patients.Frontiers in immunology · 2026Trial
- Proliferative glomerulonephritis with monoclonal IgG3 deposits: A case series.Journal of translational autoimmunity · 2026Article
- Monoclonal Gammopathy of Thrombotic Significance.American journal of hematology · 2026Review
- Ten tips for the diagnosis and management of nephrotic syndrome.Clinical kidney journal · 2026Review
- Monoclonal and monotypic immunoglobulin-related kidney diseases in young people: literature review including evolving entities.Pediatric nephrology (Berlin, Germany) · 2026Review
- C3 Glomerulopathy With Occult Gammopathy Treated With Low-Dose, Fixed Duration Venetoclax.Kidney international reports · 2026Article
- Pathological diagnosis and differential considerations of renal diseases with organized deposits under an electron microscope: key points in diagnosis.Clinical and experimental nephrology · 2026Review
- Renal amyloidosis prediction in kidney disease patients accompanied by monoclonal gammopathy.British journal of haematology · 2026Article
- Article
- Long-term eculizumab treatment failure in C3 glomerulonephritis: two case reports.Clinical kidney journal · 2026Article
- Light chain-mediated acute tubulointerstitial nephritis as the sole manifestation of monoclonal gammopathy of renal significance in a young adult.BMJ case reports · 2026Article
- C3 glomerulopathy in transplant "like yet unlike native": Pathophysiology, recent advances in therapeutics and evolving paradigms.World journal of transplantation · 2026Review
- Recurrent IgA1-λ-Type PGNMID Achieving Remission with Conventional Immunosuppressive Therapy.Internal medicine (Tokyo, Japan) · 2026Article
- Executive summary of the European consensus report on the diagnosis and treatment of monoclonal gammopathy of renal significance.Clinical kidney journal · 2026Review
- Monoclonal gammopathy of clinical significance: a multisystem review.Blood cancer journal · 2026Review
- A rare case of renal AHL amyloidosis with marked complement deposition: clinicopathologic and proteomic findings.BMC nephrology · 2026Article
- Concurrent fabry disease and monoclonal gammopathy of renal significance: a case report.BMC nephrology · 2026Article
- Light Chain Deposition Disease With Trace Monoclonal Proteinemia as Severe Renal Failure: A Case Image.Clinical case reports · 2026Article
- Clinical Determinants of Urinary Podocyte Biomarkers and Their Feasibility in Paraprotein-Related Kidney Disease.Diagnostics (Basel, Switzerland) · 2026Article
222 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
33 authors at 20 institutions in 8 countries.
Funding
Abstract
The term monoclonal gammopathy of renal significance (MGRS) was introduced by the International Kidney and Monoclonal Gammopathy Research Group (IKMG) in 2012. The IKMG met in April 2017 to refine the definition of MGRS and to update the diagnostic criteria for MGRS-related diseases. Accordingly, in this Expert Consensus Document, the IKMG redefines MGRS as a clonal proliferative disorder that produces a nephrotoxic monoclonal immunoglobulin and does not meet previously defined haematological criteria for treatment of a specific malignancy. The diagnosis of MGRS-related disease is established by kidney biopsy and immunofluorescence studies to identify the monotypic immunoglobulin deposits (although these deposits are minimal in patients with either C3 glomerulopathy or thrombotic microangiopathy). Accordingly, the IKMG recommends a kidney biopsy in patients suspected of having MGRS to maximize the chance of correct diagnosis. Serum and urine protein electrophoresis and immunofixation, as well as analyses of serum free light chains, should also be performed to identify the monoclonal immunoglobulin, which helps to establish the diagnosis of MGRS and might also be useful for assessing responses to treatment. Finally, bone marrow aspiration and biopsy should be conducted to identify the lymphoproliferative clone. Flow cytometry can be helpful in identifying small clones. Additional genetic tests and fluorescent in situ hybridization studies are helpful for clonal identification and for generating treatment recommendations. Treatment of MGRS was not addressed at the 2017 IKMG meeting; consequently, this Expert Consensus Document does not include any recommendations for the treatment of patients with MGRS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.